These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9436636)

  • 1. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
    Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
    Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose escalation of epirubicin in the CEOP-BLEO regimen: a controlled clinical trial comparing standard doses for the treatment of diffuse large cell lymphoma.
    Avilés A; Calva A; Díaz-Maqueo JC; Talavera A; Huerta-Guzmán J; Vásquez E
    Leuk Lymphoma; 1997 Apr; 25(3-4):319-25. PubMed ID: 9168442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
    Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
    Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
    Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
    Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
    Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.
    De Lena M; Maiello E; Lorusso V; Brandi M; Calabrese P; Romito S; Mazzei A; Marzullo F
    Med Oncol Tumor Pharmacother; 1989; 6(2):163-9. PubMed ID: 2473364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
    Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
    Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
    Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
    Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
    Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
    J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
    Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
    Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
    Chamorey E; Gressin R; Peyrade F; Rossi JF; Lepeu G; Foussard C; Harrousseau JL; Fabbro M; Richard B; Delwail V; Maisonneuve H; Vilque JP; Thyss A
    Oncology; 2005; 69(1):19-26. PubMed ID: 16088231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
    Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
    [No Abstract]   [Full Text] [Related]  

  • 15. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
    Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
    N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEOP/PEB alternating chemotherapy in advanced intermediate and high-grade non-Hodgkin's lymphomas.
    Abate G; Tafuto S; Romano A; Gailli E; Corazzelli G
    Haematologica; 1992; 77(4):322-5. PubMed ID: 1385277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
    Chim CS; Kwong YL; Lie AK; Lee CK; Liang R
    Hematol Oncol; 1998 Sep; 16(3):117-23. PubMed ID: 10235070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy in the treatment of aggressive diffuse large B-cell lymphoma: malignant lymphoma.
    Avilés A; Nambo MJ; Neri N; Talavera A; Castañeda C; Murillo E; Cleto S; Huerta-Guzmán J
    Med Oncol; 2004; 21(3):269-72. PubMed ID: 15456955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.